TVM Capital Healthcare, a healthcare expansion and growth capital investment firm, today declared an investment of 35million USD to Boston Oncology which is a leading local provider of specialty bio-generic drugs in Saudi Arabia.
Boston Oncology Arabia, with its headquarters in Riyadh and a production site in Sudair Industrial City, develops and manufactures internationally licensed, best-in-class treatments locally to supply crucial medicines for critical illnesses. It meets the growing demand for locally manufactured, life-saving specialty drug treatments in Saudi Arabia, and also aligns itself with Saudi Arabia’s Vision 2030 by supplying critical care medicines through local manufacturing.
By using already approved formulations and leveraging international relationships for licensing, Boston Oncology Arabia aims to provide high-quality, locally manufactured generics and biosimilar drugs. TVM Capital Healthcare will expedite the company’s manufacturing processes and provide strategic support through its global network leveraging international relationships for licensing from Western and Eastern markets.
“Boston Oncology Arabia’s localization model is specifically designed to create value in complex and competitive markets. TVM Capital Healthcare’s support enables us to strengthen our position and bring cutting-edge, specialized manufacturing to the GCC and MENA region, impacting the lives of millions of patients,” said Abdullah Baaj, MD, PharmD, Founder & CEO of Boston Oncology Arabia.
This marks a significant step towards advancing healthcare in the Kingdom, enhancing local drug production capabilities, and ultimately improving patient access to essential and innovative treatments.
